Rankings
▼
Calendar
FULC
Fulcrum Therapeutics, Inc.
$411M
Q4 2018 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$9M
Net Income
-$9M
EPS (Diluted)
$-0.52
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$6M
Free Cash Flow
-$10M
Stock-Based Comp.
$762,000
Balance Sheet
Total Assets
$86M
Total Liabilities
$10M
Stockholders' Equity
$76M
Cash & Equivalents
$73M
← FY 2018
All Quarters
Q1 2019 →
FULC Q4 2018 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
